A detailed history of Diametric Capital, LP transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Diametric Capital, LP holds 3,240 shares of GILD stock, worth $292,215. This represents 0.16% of its overall portfolio holdings.

Number of Shares
3,240
Holding current value
$292,215
% of portfolio
0.16%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$66.59 - $83.99 $215,751 - $272,127
3,240 New
3,240 $271,000
Q3 2019

Nov 13, 2019

SELL
$62.51 - $69.0 $1.89 Million - $2.09 Million
-30,315 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$61.87 - $69.38 $1.88 Million - $2.1 Million
30,315 New
30,315 $2.05 Million
Q1 2019

May 15, 2019

SELL
$62.53 - $70.05 $3.03 Million - $3.4 Million
-48,511 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$60.54 - $79.0 $53,275 - $69,520
880 Added 1.85%
48,511 $3.03 Million
Q3 2018

Nov 14, 2018

BUY
$71.28 - $78.92 $3.4 Million - $3.76 Million
47,631 New
47,631 $3.68 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Diametric Capital, LP Portfolio

Follow Diametric Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Diametric Capital, LP with notifications on news.